-
Mashup Score: 103/28/2022 - 2 year(s) ago
Clearside Investor and Media Contacts: Jenny Kobin Remy Bernarda ir@clearsidebio.com (678) 430-8206 Bausch Health Investor Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 865-3855 (877) 281-6642 (toll free) Bausch Health Media Contact: Lainie Keller lainie.keller@bauschhealth.com (908) 927-1198 BAUSCH + LOMB AND CLEARSIDE BIOMEDICAL ANNOUNCE THE U.S….
Source: Bausch ConsumerCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 6FDA APPROVES BAUSCH + LOMB CLEARVISC™ DISPERSIVE OPHTHALMIC VISCOSURGICAL DEVICE (OVD) - 3 year(s) ago
New OVD Offers Exceptional Corneal Protection, Visibility During Ophthalmic Surgery
Source: Bausch ConsumerCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 2Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System for enVista® Toric and Monofocal Preloaded Intraocular Lenses - 4 year(s) ago
Bausch + Lomb, a leading global eye health company, today announced the introduction of the SimplifEYE™ intraocular lens (IOL) delivery system, which is available exclusively for the enVista® MX60PL and the enVista® toric MX60PT, the first preloaded toric IOL available in the United States.
Source: Bausch ConsumerCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0
New Instrument to be Featured During American Society of Retinal Specialists Virutal Meeting
Source: Bausch ConsumerCategories: Latest Headlines, OphthalmologyTweet
NEWS: @BauschLomb today announced the U.S. commercial launch of XIPERE®. The launch comes after #FDA approval in October 2021. https://t.co/w2Uk0079n2 #Ophthalmology #Clinical #Treatment #Uveitis